Got Patients With Refractory axSpA or PsA? Consider This Option

(MedPage Today) — Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn’t respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should still be considered in such…

Source link : https://www.medpagetoday.com/rheumatology/arthritis/116666

Author :

Publish date : 2025-07-25 12:48:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Got Patients With Refractory axSpA or PsA? Consider This Option

Case Reports Describe Itch Relief With Nemolizumab

Hulk Hogan Dead at 71 Following Cardiac Arrest

Related Posts

CDC Panel Stops Endorsing COVID Shots, Pushes for ‘Choice’

WHO Says 31 of 38 Ebola Cases in Congo Have Resulted in Deaths

A Dozen More Charged in Alleged Massive Nursing Diploma Scam

Full Scalp Hair Regrowth Possible With Oral JAK Inhibitor

ACIP Is Now Obsolete. Here’s Where Medicine Can Look Instead.

‘War on Cancer’ Death Knell? Looming Budget Cuts; Tattoos and Melanoma Risk

CDC Panel Stops Endorsing COVID Shots, Pushes for ‘Choice’

WHO Says 31 of 38 Ebola Cases in Congo Have Resulted in Deaths

A Dozen More Charged in Alleged Massive Nursing Diploma Scam

Full Scalp Hair Regrowth Possible With Oral JAK Inhibitor

ACIP Is Now Obsolete. Here’s Where Medicine Can Look Instead.

‘War on Cancer’ Death Knell? Looming Budget Cuts; Tattoos and Melanoma Risk

Doctors Report Confusion, Hurdles to Getting COVID-19 Shots for Kids

Unforgeable quantum money can be stored in an ultracold ‘debit card’

Categories

Archives